A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with The Novel Antibody NZ-16 for Malignant Mesothelioma
Purpose This study aimed to evaluate the potential of podoplanin (PDPN)-targeted alpharadiotherapy (RIT) for treating malignant mesothelioma.Methods A newly developed anti-PDPN antibody, NZ-16, and a previous anti-PDPN antibody, NZ-12, were assessed. The in vitro properties of radiolabeled antibodies were evaluated by cell binding and competitive inhibition assays using PDPN-expressing NCI-H226 (H226) mesothelioma cells. The biodistribution of 111 In-labeled antibodies was studied indoi:10.21203/rs.3.rs-691419/v1 fatcat:lwkprmreyfeevf3xsjd4vkyqua